La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Opthea Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Fred Guerard

Amministratore delegato

US$1.5m

Compenso totale

Percentuale dello stipendio del CEO	24.9%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Fred Guerard rispetto agli utili di Opthea?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	US$1m	US$373k	-US$220m

Compensazione vs Mercato: La retribuzione totale di Fred ($USD 1.50M ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 886.63K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Fred con le performance aziendali.

AMMINISTRATORE DELEGATO

Fred Guerard (52 yo)

less than a year

Mandato

US$1,496,440

Compensazione

Dr. Frederic Guerard, also known as Fred, Pharm. D., M.S., is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at LENZ Therapeutics, Inc. since September 20...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Frederic Guerard	Chief Executive Officer	less than a year	US$1.50m	Nessun dato
Megan Baldwin	Founder	no data	US$1.36m	0.016% $ 154.2k
Karen Adams	VP of Finance & Company Secretary	3.3yrs	US$466.17k	0% $ 0
Daniel Geffken	Interim CFO	no data	Nessun dato	Nessun dato
Kevin Bitter	VP of Strategy & Corporate Development	no data	Nessun dato	Nessun dato
Sarika Gulhar	Executive Director of Human Resources	1.7yrs	Nessun dato	Nessun dato
Michael Gerometta	Head of Chemistry	15.8yrs	US$197.04k	Nessun dato
Kenneth Sall	Chief Medical Officer	1.2yrs	Nessun dato	Nessun dato
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	Nessun dato	Nessun dato
Julie Clark	Senior Vice President of Clinical Development	less than a year	Nessun dato	Nessun dato
Arshad Khanani	Chief Medical Advisor & Chairman of Medical Advisory Board	less than a year	Nessun dato	Nessun dato
Jen Watts	VP Global Clinical Operations	no data	Nessun dato	Nessun dato

0.8yrs

Durata media

52.5yo

Età media

Gestione esperta: Il team dirigenziale di OPT non è considerato esperto (durata media 1.1 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Megan Baldwin	Founder	no data	US$1.36m	0.016% $ 154.2k
Arshad Khanani	Chief Medical Advisor & Chairman of Medical Advisory Board	less than a year	Nessun dato	Nessun dato
Jeremy Levin	Chairperson	3.9yrs	US$309.43k	0.0051% $ 49.8k
Jason Slakter	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Quinton Oswald	Independence Non-Executive Director	2.4yrs	US$135.81k	Nessun dato
Julia Haller	Independent Non-Executive Director	3.3yrs	US$170.25k	Nessun dato
Lawrence Gozlan	Independent Non-Executive Director	4.2yrs	US$790.52k	0.15% $ 1.5m
Sujal Shah	Independent Non-Executive Director	less than a year	US$16.72k	Nessun dato
Anshul Thakral	Non-Executive Director	1.3yrs	US$103.72k	Nessun dato
Charles Wykoff	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Susan Orr	Independent Non-Executive Director	2.4yrs	US$130.26k	Nessun dato
Tim Jackson	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato

2.4yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di OPT non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

Opthea Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Opthea Limited Announces Executive Changes

Opthea Limited Announces Board Appointments

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Recent updates

Forecast to breakeven in 2027

Opthea Limited Announces Executive Changes

New minor risk - Profitability

Full year 2024 earnings released: US$0.34 loss per share (vs US$0.32 loss in FY 2023)

Forecast to breakeven in 2027

New minor risk - Profitability

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

New major risk - Financial position

New minor risk - Profitability

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.14 loss in FY 2021)

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: AU$1.78

New 90-day low: AU$1.81

New 90-day low: AU$2.11

New 90-day low: AU$2.30

Opthea Limited' ADR Deleted from Other OTC

Opthea Limited Appoints Dr. Jeremy Levin as Director

Geoffrey Kempler Retires as A Director of Opthea Limited

New 90-day high: AU$3.03

Opthea Limited Announces Board Changes

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

New 90-day high: AU$2.94

Opthea Limited(ASX:OPT) dropped from S&P/ASX Emerging Companies Index

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione